MarketPulse
X

$XOMAO

9 articles found
4 positive
5 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Halper Sadeh Llc

Law Firm Probes Four Companies Over Potential M&A Fairness Violations

Law firm probes four companies over potential M&A fairness violations and fiduciary duty breaches regarding shareholder consideration.
OGNXOMAXOMAOXOMAPHLX+1shareholder rightsfiduciary duty
GlobeNewswire Inc.GlobeNewswire Inc.··Schall Law Firm

XOMA Royalty Faces Fiduciary Duty Probe Over $739M Ligand Acquisition

Schall Law Firm investigates XOMA Royalty's $739M Ligand acquisition for potential fiduciary duty breaches; shareholders invited to participate.
LGNDXOMAXOMAOXOMAPshareholder rightsacquisition
GlobeNewswire Inc.GlobeNewswire Inc.··Halper Sadeh Llc

Legal Firm Probes Four Companies' Acquisition Deals for Fair Value Concerns

Halper Sadeh LLC investigates $OGN, $XOMA, $RMAX, $SLNO acquisitions for potential shareholder harm and fiduciary breaches.
OGNSLNOXOMAXOMAOXOMAP+1shareholder rightsacquisition
BenzingaBenzinga··Vandana Singh

Ligand Pharmaceuticals Acquires XOMA for $739M to Expand Royalty Portfolio

Ligand Pharmaceuticals acquires XOMA Royalty for $739M, immediately accretive to EPS with 2026 guidance raised to $8.50–$9.50 per share.
LGNDXOMAXOMAOXOMAPacquisitionM&A
GlobeNewswire Inc.GlobeNewswire Inc.··Monteverde & Associates Pc

Class Action Firm Probes XOMA-Ligand Deal: Shareholders Question $39 Acquisition Price

Monteverde & Associates investigates XOMA Royalty's $39-per-share sale to Ligand Pharmaceuticals, questioning whether terms are fair to shareholders.
LGNDXOMAXOMAOXOMAPHLX+3acquisitionclass action
GlobeNewswire Inc.GlobeNewswire Inc.··Juan Monteverde, Monteverde & Associates Pc

Legal Firm Opens Investigation Into Miluna Acquisition Deal as Shareholder Concerns Mount

Legal firm Monteverde & Associates investigates Miluna Acquisition Corp.'s merger with CADV Ventures amid fairness concerns, soliciting shareholder input for potential class action litigation.
XOMAXOMAOXOMAPHLXMMTX+2class actionmerger investigation
BenzingaBenzinga··Na

Ligand to Acquire XOMA Royalty for $739M, Bolstering Biopharma Portfolio to 200+ Assets

Ligand Pharmaceuticals to acquire XOMA Royalty for $39/share in $739M cash deal, expanding portfolio and raising 2026 EPS guidance.
LGNDXOMAXOMAOXOMAPacquisitionbiopharmaceutical
BenzingaBenzinga··Globe Newswire

XOMA Royalty Declares Quarterly Preferred Dividends Ahead of April Payout

XOMA Royalty authorizes quarterly preferred dividends: $0.53906 per Series A share and $0.52344 per Series B depositary share, payable April 15, 2026.
XOMAXOMAOXOMAPdividend paymentpreferred stock dividends
GlobeNewswire Inc.GlobeNewswire Inc.··Na

XOMA Royalty Surges on 68% Royalty Growth and Aggressive Portfolio Expansion

XOMA Royalty reports $50M+ cash receipts in 2025, with royalties up 68% YoY. Company adds 22 assets, completes seven acquisitions, and repurchases $16M in shares.
DAWNRZLTGOSSZVRAMIRM+3acquisitionsshare buyback